NCT05564377 2026-04-21
Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
Clinical Trials
16 trialsNCT07405801 2026-04-20
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT04606446 2026-04-16
KAT6
Pfizer
Phase 2 Recruiting
NCT06179303 2026-04-16
Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
University of Washington
Phase 2 Recruiting
NCT04920708 2026-04-14
FAIM
Royal Marsden NHS Foundation Trust
Phase 2 Active not recruiting
NCT02630693 2026-04-13
Two Different Schedules of Palbociclib + Second Line Endocrine Therapy in Estrogen Receptor Positive, HER2 Neg Advanced/Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Completed
NCT04553133 2026-04-13
PF-07104091 as a Single Agent and in Combination Therapy
Pfizer
Phase 2 Active not recruiting
NCT06979596 2026-04-13
OMAHA-015
Merck Sharp & Dohme LLC
Phase 2 Recruiting
NCT07368998 2026-04-13
optINAVO
Hoffmann-La Roche
Phase 2 Recruiting
NCT04524000 2026-04-08
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant in Japanese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT04796623 2026-04-08
A Study of TQB3616 Capsules Combined With Fulvestrant Injection in Subjects With Advanced Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2 Completed
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT04544189 2026-04-02
Study Assessing the Efficacy and Safety of Treatment With Alpelisib Plus Fulvestrant Versus Placebo Plus Fulvestrant in Chinese Men and Postmenopausal Women With Advanced Breast Cancer
Novartis
Phase 2 Active not recruiting
NCT06145308 2026-04-02
Precision Treatment of Recurrent/Metastatic Salivary Gland Carcinoma Guided by Molecular Typing
Peking Union Medical College
Phase 2 Recruiting
NCT05601440 2026-03-27
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
Canadian Cancer Trials Group
Phase 2 Recruiting
NCT07498478 2026-03-27
Efficacy and Safety of Tinengotinib Tablets Combined With Fulvestrant Injection in Patients With HR Positive and HER-2 Negative Recurrent or Metastatic Breast Cancer Who Have Failed Prior Treatment
TransThera Sciences (Nanjing), Inc.
Phase 2 Recruiting